Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max Greenberg

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Nature Communications|April 20, 2022
TNF is a potential therapeutic target to suppress prostatic inflammation and hyperplasia in autoimmune diseaseRenee E Vickman, LaTayia Aaron-Brooks, Renyuan Zhang, et al.
Cell Reports|December 16, 2017
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient CareDavid P Kodack, Anna F Farago, Anahita Dastur, et al.
Oncogene|July 21, 2019
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancerSana Raoof, Iain J Mulford, Heidie Frisco-Cabanos, et al.
Cancer Cell|October 8, 2021
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigmsHaichuan Hu, Zofia Piotrowska, Patricia J Hare, et al.
Cancer Discovery|April 22, 2026
BLOCKADE OF TUMOR-INTRINSIC TGF-Β SIGNALING DRIVES HYPERPROGRESSION IN SMALL CELL LUNG CANCERBrett A Schroeder, Chirayu Mohindroo, Anna-Lena Meinhardt, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Nature Communications|April 20, 2022
TNF is a potential therapeutic target to suppress prostatic inflammation and hyperplasia in autoimmune diseaseRenee E Vickman, LaTayia Aaron-Brooks, Renyuan Zhang, et al.
Cell Reports|December 16, 2017
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient CareDavid P Kodack, Anna F Farago, Anahita Dastur, et al.
Oncogene|July 21, 2019
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancerSana Raoof, Iain J Mulford, Heidie Frisco-Cabanos, et al.
Cancer Cell|October 8, 2021
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigmsHaichuan Hu, Zofia Piotrowska, Patricia J Hare, et al.
Cancer Discovery|April 22, 2026
BLOCKADE OF TUMOR-INTRINSIC TGF-Β SIGNALING DRIVES HYPERPROGRESSION IN SMALL CELL LUNG CANCERBrett A Schroeder, Chirayu Mohindroo, Anna-Lena Meinhardt, et al.
Pageof 2